Somewhere in the tangled archives of global branding, a cautionary tale is unfolding in real time — and it belongs to Haima. For nearly three decades, that name has meant automobiles: first as a joint-venture partner of Mazda in Hainan province, later as an independent Chinese marque building sedans, SUVs, and the curious little Bird Electric EV1. But search for "Haima" today, and the top results are increasingly likely to concern freeze-dried synthetic blood platelets, battlefield trauma care, and a Cleveland-based biotech firm called Haima Therapeutics. The car company, quietly, is being erased from its own name.
This is not a trivial matter of search-engine hygiene. A brand name is the single most valuable asset a manufacturer owns, and its meaning is dictated not by the company that registers it but by the public that encounters it. When Haima Therapeutics licenses platelet technology from Case Western Reserve University and earns coverage in *EurekAlert!* and *WKYC* for a shelf-stable artificial platelet that could stop internal bleeding on the battlefield, it plants a flag in the public imagination. Every subsequent mention of "Haima" in a medical or scientific context pushes the automaker further down the page — and further from relevance.
A Name Is a Finite Resource
The irony is sharp. Chinese automakers have spent two decades fighting for global name recognition, investing billions in exports, motorsport, and electrification to be known outside their home market. Haima — the automaker — has achieved a kind of recognition, just not the kind it wanted. Its name now signals life-saving medical innovation in Ohio laboratories rather than sheet metal from Haikou. The company did not choose this association, cannot control it, and will almost certainly never escape it.
None of this is to suggest that Haima Therapeutics has done anything wrong. It has done everything right: licensed breakthrough science, pursued a genuine unmet need in trauma medicine, and earned the press that follows. The lesson is not about ethics but about the brutal arithmetic of attention. A name is a finite resource, and two organisations cannot hold the same one in the public mind indefinitely. One will win. On current evidence, the automaker is not winning.
A Fight on Two Fronts
Worse, the collision arrives at a moment of genuine vulnerability for the automotive Haima. Recent reporting from *36Kr* noted that news of a strategic alliance between GAC and FAW sent shares of Zotye and Haima surging to their daily limits, sparking speculation about a new wave of consolidation among Chinese automakers. Meanwhile, *Gasgoo* reported that the vehicle production qualifications of eight established automakers had been permanently frozen — part of an intensifying elimination race in China's overcrowded auto industry. Haima was compelled to issue a public denial, with outlets including 网通社 confirming that its production license remains valid.
A company fighting for its industrial life should be fighting for mindshare too — yet its name is being colonised by a platelet substitute. That is the cruelest part of the story: the battle for survival and the battle for identity are being fought simultaneously, and the second one is quietly being lost while everyone watches the first.
The Horse That Carried Emperors
There is a deeper cultural layer here that makes the situation almost literary. *Haima* in Mandarin means "sea horse" — a creature of myth and delicacy. In Chinese tradition, the celebrated "blood-sweating horses" of Ferghana were auspicious symbols of imperial power, as *Sixth Tone* recently explored. That a car brand named for a horse should lose its identity to a technology named for blood is an accident of phonetics with the weight of fable. The horse once carried emperors; now the word carries platelets.
It is the kind of coincidence a novelist would reject as too neat, and yet it is happening in real time, in real search results, to a real company with real employees and real cars. The poetry of it does not soften the commercial damage. If anything, it sharpens the point: names carry histories, and histories can be hijacked by nothing more than a shared string of letters.
What Comes Next
For Haima the car company, the path forward is unglamorous but clear: sharpen the identity, lean harder on model names like the Bird Electric EV1, and accept that the corporate name may never again be the first thing a stranger finds. For the rest of the industry, the episode is a reminder that in a globalised information economy, your brand is only yours until someone else's breakthrough borrows it. Names, like platelets, can be repurposed — and once they are, they do not always return.
A car brand, at its core, is a promise about motion: that a machine will start, pull, corner, and carry you somewhere worth going. Haima built that promise into metal for the better part of thirty years. Whether the name still carries it — or whether it now belongs to a laboratory in Cleveland — is a question no engineering department can answer alone.